The imbalance of CDKN2A, IL1R2, and RFC4 could promote the proliferation of cancer cells, which is closely related to the progress of cervical cancer, and might be a potential diagnostic marker and therapeutic drug targets (Niu et al., 2017). The gene discussed is IL1R2; the disease is cervical carcinoma.